1xbet 한국 Pharmaceutical Co., Ltd.

1xbet 한국 Pharmaceutical Co., Ltd. (1xbet 한국) announces the revision of the license agreement signed in September 2021 with Sumitomo Pharma Co., Ltd. (Sumitomo Pharma) and its U.S. subsidiary, Sumitomo Pharma America, Inc. (SMPA).

1xbet 한국 originally entered into a licensing agreement with Sumitomo Pharma and SMPA for worldwide joint development and commercialization of four novel candidate compounds under development in the psychiatric and neurology area, namely SEP-363856 (hereinafter ulotaront), SEP-4199, SEP-378614, and SEP-380135. Following revision of the license agreement, 1xbet 한국 holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide.

Abstracts from the Revised Agreement:

• Of the four compounds that were under the original licensing agreement, SEP-4199 and SEP-378614 have been excluded through the revision. 1xbet 한국 has obtained from SMPA exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 for all indications worldwide.
• Should 1xbet 한국 succeed in the development and commercialization of ulotaront and SEP-380135, 1xbet 한국 will pay up to a total of 30 million US dollars (approximately 4.5 billion yen) as milestones for both compounds, as well as royalties based on sales.
• No upfront payment will be incurred in relation to this revised agreement. Except for certain studies, 1xbet 한국 will bear the full cost of the studies being conducted by both Sumitomo Pharma Group and 1xbet 한국 from January 2024.

Ulotaront is a small-molecule oral drug that is a TAAR1 (trace amine-associated recep1xbet 한국r 1) agonist with sero1xbet 한국nin 5-HT_1Aagonist activity, 1xbet 한국 does not bind to dopamine D₂or sero1xbet 한국nin 5-HT_2Areceptors. FDA expressed relatively positive feedback about the results of two clinical trials targeting schizophrenia. As a result of comprehensively examining the current status of the ongoing phase 2/3 trials targeting adjunctive treatment for major depressive disorder (aMDD) and generalized anxiety disorder (GAD), as well as marketability, 1xbet 한국 determined that ulotaront still has high potential and decided to continue its development.

It has been hypothesized based on non-clinical studies that SEP-380135 may be effective against behavioral 1xbet 한국 psychological symptoms associated with dementia, such as agitation, aggression, psychomotor hyperactivity, 1xbet 한국 depression. Phase 1 trials are being conducted in the United States.

1xbet 한국 will continue to develop ulotaront and SEP-380135 and aims to provide new drugs that contribute to people around the world suffering from mental disorders.

Reference press releases:

(September 30, 2021) Sumitomo Dainippon Pharma and 1xbet 한국 Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds

Sumitomo Dainippon Pharma and 1x 베팅 주소 Announce

(July 31, 2023) Sumitomo Pharma and 1xbet 한국 Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Sumi1xbet 모바일mo Pharma and Otsuka Announce 1xbet